Management of cytomegalovirus in hematopoietic stem cell transplant recipients: A review of novel pharmacologic and cellular therapies

Author:

Kronfli Nadine1,Haider Shariq12

Affiliation:

1. Division of Infectious Diseases, Hamilton Health Sciences, Hamilton, Ontario, Canada

2. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Abstract

Background: Despite diagnostic and therapeutic advances, cytomegalovirus (CMV) infection has remained a significant complication after hematopoietic stem cell transplantation (HSCT). The widespread use of pre-emptive antiviral therapy has reduced, but not eliminated, the occurrence of early CMV infection. The epidemiological shift of CMV infection, requiring repeated and prolonged treatment courses, creates an increasing need for novel antiviral drugs. This is an exciting time in the evolution of pharmacologic anti-CMV therapies. Objective: This review article provides an update on the therapeutic options for treatment of CMV in HSCT recipients, focusing on new pharmacologic agents—including maribavir, letermovir, brincidofovir, leflunomide, and artesunate—as well on as the emerging concept of cellular therapies and the future of a CMV vaccine. Results: In the past few years, encouraging preliminary data has emerged for both new pharmacologic therapies and cellular therapies; however, current evidence does not support their routine use for CMV prophylaxis or treatment. Conclusions: Despite the lack of data substantiating the routine use of new pharmacologic and cellular therapies, numerous trials, many of which are either phase III or randomized, are currently underway and will undoubtedly influence the use of these agents in the near future. CMV vaccines offer a safe and effective alternative to pharmacologic and cellular therapies as we await results of phase III clinical trials.

Publisher

University of Toronto Press Inc. (UTPress)

Subject

Infectious Diseases,Microbiology (medical)

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3